This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.
Not a healthcare professional? Browse:
This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
What's new
Congresses & Events
7 December, 2024
Congresses & Events
6 December, 2024
Congresses & Events
24 November, 2024
This presentation describes the week 16 (interim) results of the phase 3b/4 SALWEEN study. SALWEEN is investigating the efficacy, safety and durability of faricimab▼ in patients with polypoidal choroidal vasculopathy (PCV) from Asian countries, a subtype of nAMD which is highly prevalent in Asia and a population underrepresented in the phase 3 TENAYA/LUCERNE trials. Interim efficacy and safety results have demonstrated robust improvements in vision and anatomy, and complete closure and inactivation of polypoidal lesions in the majority of patients. Faricimab▼ was well tolerated and consistent with the known safety profile of faricimab▼.
Congresses & Events
24 November, 2024
This presentation describes the results of an interim analysis of treatment-naïve patients (baseline to month 6) receiving faricimab▼ in the innovative real-world VOYAGER study. The global VOYAGER study investigates the real-world effectiveness, safety, treatment patterns and anatomical features affecting vision outcomes with faricimab▼ in patients with nAMD and DME on a global level. Treatment-naive eyes achieved visual gains and anatomic improvements during the follow-up period.
Congresses & Events
22 November, 2024
This presentation reports data supporting patient preference for the Port Delivery System with ranibizumab vs intravitreal injections in the phase 3 Pagoda trial for patients with DME at 1 year.
Congresses & Events
22 November, 2024
Efficacy and safety results from Pavilion year 2 are presented, demonstrating maintenance of DRSS improvement over 2 years, along with safety data consistent with primary analyses.
Congresses & Events
22 November, 2024
Clinical Trials
22 November, 2024
Status: Completed
Educating on current and novel biomarkers for neurodegenerative disorders
Ask us a question and request information about Roche products or services.
If you have experienced potential side effects with a Roche product you can report it here.
If you suspect a potential defect or a Roche product has not met your expectations you can report it here.
Request an assessment if your product was stored outside the recommended temperature range.
On this global platform you will find tailored, evidence-based, balanced, and up-to-date medical information from Roche.This website is intended to provide medical information relating to questions asked about Roche medicines.
This website is not country specific and therefore may contain medical information on Roche medicines that is not applicable to your country. Please refer to your country prescribing information and local package insert.
Some medical information contained on this site may not be consistent with the locally approved indications for the specific Roche medicine. If you are a patient on a Roche medicine, please contact your treating doctor for medical support and before making any changes to your treatment.